AlphaV-integrins mediate the mechanoprotective action of osteopontin in podocytes.
Increased mechanical load in podocytes due to glomerular hypertension is one of the important factors leading to podocyte damage and chronic kidney disease. In previous studies, we have shown that mechanical stretch increases osteopontin (OPN) expression in podocytes and that exogenous OPN is mechanoprotective via facilitating cytoskeletal reorganization of podocytes. In the present study, we asked whether the mechanoprotective effect of OPN in podocytes is mediated through specific integrins and whether endogenous OPN of podocytes is required for mechanoprotection. Conditionally immortalized mouse podocytes and primary podocytes (PP) from OPN-/- and OPN+/+ mice were used. Cyclic biaxial mechanical stretch (0.5 Hz, 7% linear strain) was applied for up to 3 days. Stretch-induced cell loss was ∼30% higher in OPN-/- PP compared with OPN+/+ PP. Increased cell loss of OPN-/- PP was rescued by OPN coating. Analysis of integrin expression by RT-PCR, application of RGD and SLAYGLR peptides and anti-integrin antibodies, small-interfering RNA knockdown of integrins, and application of kinase inhibitors identified αV-integrins (αVβ1, αVβ3, and αVβ5) to mediate the mechano-protective effect of OPN in podocytes involving focal adhesion kinase, Src, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase. Our results demonstrate that endogenous OPN of podocytes plays a nonredundant role in podocyte adaptation to mechanical stretch, and that OPN signaling via α(V)-integrins may represent a relevant therapeutical target in podocytes.
Department of Anatomy and Cell Biology, University of Greifswald, Greifswald, Germany.
Sandra
S
Schordan
Eric
E
Schordan
Karlhans
K
Endlich
Nicole
N
Endlich
D000199:Actins / Q000648:ultrastructure; D000818:Animals; D002478:Cells, Cultured; D039564:Integrin alphaV / Q000096:biosynthesis / Q000494:pharmacology*; D048670:MAP Kinase Kinase 4 / Q000037:antagonists & inhibitors / Q000502:physiology; D008465:Mechanoreceptors / Q000502:physiology*; D051379:Mice; D053495:Osteopontin / Q000235:genetics / Q000494:pharmacology* / Q000502:physiology; D050199:Podocytes / Q000187:drug effects* / Q000502:physiology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D013314:Stress, Mechanical
D000199:Actins; D039564:Integrin alphaV; D047428:Protein Kinase Inhibitors; D053495:Osteopontin; D048670:MAP Kinase Kinase 4